Creative Medical Technology Holdings, Inc. has recently provided an update on its latest business activities, showcasing continued advances in the development of regenerative therapies. The biotechnology company is focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics. The company’s recent clinical, regulatory and commercial developments further validate their business model of developing best-in-class regenerative therapies that address multiple indications and growing end markets.
One of the significant updates includes the US Food and Drug Administration clearing the company’s Investigational New Drug application for type 1 diabetes with CELZ-201 (AlloStem). Institutional Review Board approval was granted in February 2023 to proceed with its clinical trial. Positive follow-up data was also announced in April 2023 using CELZ-001 cells to treat patients with type 2 diabetes. At a six-month follow-up, there were no safety concerns associated with CELZ-001.
In May 2023, the company announced positive results from a frontline pilot study for the StemSpine® procedure using AlloStem to treat chronic low back pain. It is said that this patented procedure uses AlloStemTM, which could potentially repair, remodel and improve blood supply around the disc and lower back.
The Company also reported progress in continuing development of its ImmCelz® (CELZ-100) platform that empowers patient’s own cells to treat immune disorders. Independent studies confirmed that the ImmCelz® platform requires fewer donor patient cells compared to industry standards while producing more effective products.
Lastly, Creative Medical Technology Holdings maintains strong financial standing as it reports cash and certificates of deposit of $14.6 million as of March 31st without any long-term debt.
